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Abstract
Background: Compared to conventional human basal insulin (neutral protamine Hagedorn; NPH) the long-acting
analogue insulin glargine (GLA) is associated with a number of advantages regarding metabolic control,
hypoglycaemic events and convenience. However, the unit costs of GLA exceed those of NPH. This study aims to
systematically review the economic evidence comparing GLA with NPH in basal-bolus treatment (intensified
conventional therapy; ICT) of type 1 diabetes in order to facilitate informed decision making in clinical practice and
health policy.
Methods: A systematic literature search was performed for the period of January 1st 2000 to December 1st 2009
via Embase, Medline, the Cochrane Library, the databases GMS (German Medical Science) and DAHTA (Deutsche
Agentur für Health Technology Assessment), and the abstract books of relevant international scientific congresses.
Retrieved studies were reviewed based on predefined inclusion criteria, methodological and quality aspects. In
order to allow comparison between studies, currencies were converted using purchasing power parities (PPP).
Results: A total of 7 health economic evaluations from 4 different countries fulfilled the predefined criteria: 6
modelling studies, all of them cost-utility analyses, and one claims data analysis with a cost-minimisation design.
One cost-utility analysis showed dominance of GLA over NPH. The other 5 cost-utility analyses resulted in
additional costs per quality adjusted life year (QALY) gained for GLA, ranging from € 3,859 to € 57,002 (incremental
cost effectiveness ratio; ICER). The cost-minimisation analysis revealed lower annual diabetes-specific costs in favour
of NPH from the perspective of the German Statutory Health Insurance (SHI).
Conclusions: The incremental cost-utility-ratios (ICER) show favourable values for GLA with considerable variation.
If a willingness-to-pay threshold of £ 30,000 (National Institute of Clinical Excellence, UK) is adopted, GLA is cost-
effective in 4 of 6 cost utility analyses (CUA) included. Thus insulin glargine (GLA) seems to offer good value for
money. Comparability between studies is limited because of methodological and country specific aspects. The
results of this review underline that evaluation of insulin therapy should use evidence on efficacy of therapy from
information synthesis. The concept of relating utility decrements to fear of hypoglycaemia is a plausible approach
but needs further investigation. Also future evaluations of basal-bolus insulin therapy should include costs of
consumables such as needles for insulin injection as well as test strips and lancets for blood glucose self
monitoring.
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The aim of diabetes therapy has always been to mimic the
basal and mealtime components of endogenous insulin
secretion. Since intensive conventional treatment (ICT)
was introduced in the 1960s this was achieved by applying
short-acting and intermediate-acting human insulin [1].
Throughout the 1990s insulin pumps with a programma-
ble insulin secretion profile became increasingly available.
As a third option the first synthetic long-acting insulin
analogue insulin glargine (GLA) was approved by the
European Medicines Agency (EMA) and Food and Drug
Administration (FDA) in 2000 [2].
GLA is produced using a recombinant DNA technol-
ogy. After injection GLA precipitates in the subcuta-
neous tissue and the absorption into the bloodstream is
delayed. Pharmacodynamic studies showed that GLA
covers the basal demand over 24 hours. It is closer to
the physiological insulin release than intermediate-acting
NPH insulin [3].
The efficacy of GLA has been extensively studied in
type 1 diabetes. Three systematic reviews [4-6] and one
meta-regression [7] cover this topic.
As type 1 diabetes is a lifelong condition starting in
childhood, optimal metabolic control is very important to
prevent disease specific micro- and macrovascular compli-
cations. In addition, the incidence of type 1 diabetes in
children younger than 15 years is increasing in Europe,
and thus the future burden of this disease. For 2020 the
number of new cases in Europe is predicted to be 24,400
per annum. The prevalence of type 1 diabetes in children
under 15 is expected to rise by 70% [8].
The unit cost of GLA is higher than that of convention-
ally used intermediate-acting NPH insulin. As all health
care systems have to make optimal use of scarce resources,
economic evaluation of GLA is an important issue. Because
conduct and interpretation of economic evaluation is an
extensive and complex effort a systematic review of the
existing health economic evidence might be useful for
many third party payers and other decision makers in
health care.
The aim of the present study was to systematically
review the published health economic evaluations com-
paring GLA with NPH as the basal component of an
ICT in patients with type 1 diabetes.
Methods
The design of the systematic review was based on the
recommendations of the PRISMA Statement [9]. The fol-
lowing predefined criteria were applied for the inclusion of
studies:
￿ patients with type 1 diabetes only; studies, where
type 1 diabetes was mixed with type 2 diabetes or
undefined diabetes types were excluded
￿ intervention with GLA as the basal component of
intensified conventional therapy (ICT)
￿ NPH as comparator
￿ comparative health economic design: cost-minimi-
sation analysis (CMA), cost-effectiveness analysis
(CEA) cost-utility analysis (CUA) or systematic
reviews about studies of the corresponding type
￿ at least one of the following parameters as target
parameters: difference of treatment costs, incremental
direct costs, incremental indirect costs, incremental
cost-effectiveness ratio (ICER)
￿ full publication in English or German language
between January 1st 2000 and December 1st 2009. If
a full publication does not exist either a detailed
study report has to be available or a congress paper,
which contains all the necessary information for the
quality evaluation and standardised data extraction. If
the information covered by the congress paper is not
sufficient, personal correspondence with the author
has to provide all necessary information for the stan-
dardised data abstraction form.
The following electronic data bases were searched: Med-
line, Embase, Cochrane Library, National Health Service’s
Database of Abstracts of Reviews of Effects (NHS-DARE),
National Health Service Economic Evaluation Database
(NHS-HTA), as well as the German Medical Science Data-
base (GMS) of the German Institute of Medical Documen-
tation and Information (DIMDI). The database of DIMDI
also included the database of the German Agency of
Health Technology Assessment (DAHTA). For the respec-
tive search strings see Additional file 1. Additionally, a
hand search in the German Diabetology journals was con-
ducted for the years 2007 to 2009 as well as in abstract
books of relevant international scientific congresses: the
abstract databases of the Annual European respectively
the Annual International Congresses of the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR), of the Annual Scientific Sessions of the Ameri-
can Diabetes Association (ADA), of the Annual Interna-
tional Meetings and the of the Annual Meetings of the
European Association for the Study of Diabetes (EASD),
and of the Annual Meeting of the German Diabetes
Society (DDG) were scanned for relevant studies during
the period of 2007 to 2009. The manufacturer of insulin
glargine was asked to provide all relevant studies.
Two reviewers (KCK and EGH) independently
selected publications for inclusion. Differences in deci-
sions between the reviewers were resolved by consensus.
Identified records were assessed in a two-stage proce-
dure. First, title and abstract were screened for compli-
ance with the defined inclusion criteria. All double
publications were excluded, and in the case of doubt full
text publications were obtained. In the second step, full
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inclusion.
After inclusion, the quality of the remaining studies
was evaluated [10]. To assess the quality, widespread
tools are available such as the tools of Leidl et al. [11], of
Aidelsburger et al. [12], of Drummond and Jefferson [13]
or Drummond et al. [14]. As a limitation, these checklists
do not cover more recent aspects of health economic
evaluation such as complex modelling. Also the require-
ments for health economic evaluation in diabetology are
not considered. Economic analyses of diabetes mellitus
treatment should consider the chronicity of the disease
by a time horizon long enough to cover the broad
spectrum of long-term consequences and their impact on
quality of life [15]. Therefore, based on the publications
above an extended checklist was developed (see Addi-
tional file 2).
For the evaluation of claims data analyses the quality
characteristics of observational studies were applied, as
they can be deduced from the STROBE Initiative [16]:
description of setting and inclusion criteria of the study,
definition of exposition and target parameter, confounding
control, appropriate statistical analysis techniques, as well
as a consistent presentation of results.
Key elements of the studies were captured in standar-
dised abstraction forms either for modelling studies or
for observational studies.
The ICER of the included studies were transferred into
Euro values via purchasing power parities (PPP) for easier
comparison, as proposed by Welte et al. [17] and Drum-
mond et al. [18]. PPP values were obtained from the
German Federal Statistical Office [19]. Euro values were
calculated for the year of costing as used in the corre-
sponding study (see Additional file 3).
Results
The search yielded 382 publications, 267 of which were
excluded based on title and abstract screening. Follow-
ing the full text review, a total of 12 published articles
were selected for final inclusion (Figure 1): 6 modelling
studies [20-25], 1 claims data analysis [26] and 5 sys-
tematic reviews [27-31].
Two of the identified studies were based on the evalua-
tion of GLA by NICE [32] in the year 2002. One was the
report of the assessment group on the primary model
[20]. The other one was the detailed publication of the
amended final model [24], which was the basis for the
f i n a la p p r a i s a li nt h eT e c h n i c a lA p p r a i s a lG u i d a n c eb y
NICE [32].
The modelling studies were conducted in health care
systems such as Canada [21,22], Great Britain [20,23,24]
and Switzerland [25]. The claims data analysis [26] was
conducted in the German setting.
Modelling studies
Table 1 presents an overview of the 6 modelling studies
[20-25] in detail. All of the studies were conducted as
incremental cost-utility analyses.
Quality assessment of modelling studies
The results of the quality assessment are given in Table 2.
All of the modelling studies considered long-term con-
sequences of diabetes. The effectiveness data of 3 studies
[20,22,24] were based on selected randomised controlled
trials (RCTs [33-35]). The choice of the trial by Porcellati
et al. was motivated by its comparatively large sample size
and 12 months duration. The other RCTs are referred to
as being representative. Warren et al. [20] used a meta-
analysis done by themselves and one RCT [33]. One mod-
elling study [21] used a recently published meta-analysis
[5] which included 11 studies. Being most recent it should
cover most of the available evidence. McEwan et al. [23]
refer to an unpublished meta-analysis. They chose for
their 5 scenarios different values from meta-analyses on 3
different subgroups of studies: all studies, studies of ≥ 3
months duration, pre-registration studies. Brändle et al.
[25] used data from the above mentioned unpublished
meta-analysis to determine the value of HbA1c reduction.
They used data from meta-regression based on all avail-
able patient-level data from all randomized phase III and
IV clinical trials sponsored by the manufacturer of GLA
that compared GLA and NPH available in May 2004 [7] to
determine the rates of hypoglycaemia reduction in rela-
tionship to glycaemic control. Individual patient data from
other randomized phase III and IV clinical trials compar-
ing GLA and NPH retrieved from MEDLINE, EMBASE,
and BIOSIS were not available at that time [7]. This con-
cept has been discussed and accepted by other authors
[20,24].
Only the modelling study of Brändle et al. [25] consid-
ered needles, blood glucose test strips or lancets, which
contribute significantly to insulin therapy costs. Two of
the studies lack a complete description of therapy alterna-
tives and of the perspective of the economic evaluation
[21-25].
Most of the modelling studies were of good quality
regarding incremental analysis, sensitivity analysis, descrip-
tion of general results, and presentation of results per
capita as well as answering the research question. Despite
the clear guidelines of NICE for economic analysis, the
short descriptions of the models in the two studies linked
to the NICE appraisal [20,24] made it difficult to under-
stand the structure of the model, the input parameters,
and especially the use of utility values. Furthermore, in the
publication of Warren et al. [20] the description of the
results of the sensitivity analysis was limited.
Overall the included modelling studies showed an
acceptable or good quality. They had sufficient explanatory
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lin analogue (GLA) versus the selected comparator (NPH).
Input parameters: clinical effects
Table 1 gives for every modelling study the sources for
the parameters of clinical effectiveness. Most of the mod-
elling studies assumed that under treatment with GLA
compared to NPH either the metabolic adjustment
improved under a comparable frequency of hypoglycae-
mic events, or the frequency of hypoglycaemia decreased
under comparable metabolic control. Accordingly, both
studies of Warren et al. [20,24] only considered a reduc-
tion of symptomatic hypoglycaemia (-19% and -42%,
respectively) and severe hypoglycaemia (both -52%). In
sensitivity analyses these models used an additional
HbA1c reduction of 0.14%-points under GLA without
reduction of hypoglycaemia. Grima et al. [22] only used
an additional reduction of HbA1c of 0.4% points under
GLA. In a more advanced approach, McEwan et al. [23]
made use of unpublished meta-analyses with different
scenarios. In scenario 1 to 3, the risk of severe hypogly-
caemia was reduced between 25 and 28% and the risk of
nocturnal hypoglycaemia between 17 to 22% under GLA.
In scenario 4 and 5, HbA1c was reduced under GLA
additionally by 0.19% points and 0.45% points, respec-
tively, without changing the rate of hypoglycaemia.
Combined effects on hypoglycaemia and on metabolic
control were implemented in two studies: Cameron et al.
[21] used meta-analyses [5] for reduction of moderate
and severe hypoglycaemia (both -18%) combined with an
HbA1c reduction of 0.11% points. In the model of Brän-
dle et al. [25] a reduction of severe (-24%), nocturnal
(-24%) and symptomatic (-23%) hypoglycaemia was com-
bined with a HbA1c reduction of 0.19%-points.
Input parameters: utilities
Quality of life is reduced by diabetes-related long-term
macro- and microvascular complications such as coronary
heart disease comprising angina pectoris, myocardial
infarction, congestive heart failure, and nephropathy as
well as retinopathy [36]. Different approaches were used
in the included studies as shown in Table 3. Grima et al.
[22] used utilities for the different long-term consequences
of diabetes. In the case of several coexisting complications
the lowest applicable utility was used. McEwan et al. [23],
Brändle et al. [25] and Cameron and Bennett [21] used
utility decrements, summing up different coexisting dia-
betic long-term consequences and hypoglycaemia events.
Total records identified, n = 382
Medline, n = 57
Embase, n = 242
Cochrane Library, DARE,  NHS-EED,  NHS-HTA,  GMS, Springer 
publishing database incl. Pre-Print, Thieme publishing database 
incl. Pre-Print, DAHTA,  n = 79
Congress abstracts  (ADA, ISPOR European, ISPOR 
International, EASD, DDG),  n = 1
Hand search (Diabetologe, Diabetes, Stoffwechsel & Herz, 
Diabetologie & Stoffwechsel), n = 1
Reference list of included publications, n = 1
Full study report from Sanofi-Aventis, n = 1
Duplicates, n = 77
Records after duplicates removed, n = 305
Exclusion based on titel/abstract, n = 267
Full-text publications assessed for eligibility, n = 38
Exclusion based on full text, n = 26
Studies included into analysis, n = 12
Single evaluations GLA versus NPH, n = 7
Systematic reviews, n = 5
Figure 1 Flow chart of study selection. ADA = American Diabetes Association, DAHTA = Deutsche Agentur für Health Technology
Assessment, DARE = National Health Service’s Database of Abstracts of Reviews of Effects, DDG = Deutsche Diabetes Gesellschaft, EASD =
European Association for the Study of Diabetes, GLA = Insulin glargine, GMS = German Medical Science, ISPOR = International Society for
Pharmacoeconomics and Outcomes Research, NHS-EED = National Health Service Economic Evaluation Database, NHS-HTA = National Health
Service Health Technology Assessment Database, NPH = Neutral Protamine Hagedorn insulin.
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Page 4 of 13Table 1 Main characteristics of modelling studies with GLA vs.NPH (listed in order of increasing ICER in €/QALY
a)
Author/study (year)
country/perspective/time
horizon (discount rate)
initiator
Type of economic
evaluation/
methodological
approach
Effect of GLA on
HbA1c compared
to NPH
Effect of GLA on frequency
of hypoglycaemia compared
to NPH
Long-term complications
of diabetes
Utilities Results for
GLA compared
to NPH
ICERs in
€/QALY
a
Brändle et al.[25]
Switzerland
third party payer
perspective
40 years
(C 3.5%, E 3.5%)
Sanofi-Aventis
CUA
DES based on McEwan et
al. [23] and DCCT
-0.19% points
according to Mc
Ewan [23]
Symptomatic: -23%
Severe: -24%
Nocturnal: -24%
All reductions based on [7]
Reduction depending on
HbA1c reduction
Reduction by:
1. hypoglycaemia
2. fear of
hypoglycaemia
3. long-term
consequences
IU: 0.238 QALYs
more
IC: CHF 1,476
less
ICER: GLA
dominant
dominant
McEwan et al. [23]
Scenario 5
UK
NHS
40 years
(C 3.5%, E 3.5%)
Sanofi-Aventis
CUA
DES based on DCCT
-0.45% points
b - Reduction depending on
HbA1c reduction
Reduction by:
1. long-term
consequences
IU: 0.12 to 0.34
QALYs more
IC: £ 1,043 to £
1,371 more
ICER: £ 1,096/
QALY
€ 3,859
Warren et al. [24]
UK
NHS
9 years (
C 3.5%, E 3.5%)
NICE
CUA
ScHARR Model
Only in sensitivity
analysis:
-0.14% points [33]
Symptomatic: -42% [35]
Severe: -52% [35]
In sensitivity analysis
reduction depending on
HbA1c reduction
Reduction by:
1. hypoglycaemia
2. fear of
hypoglycaemia
3. long-term
consequences only in
sensitivity analysis
IU: n/a
IC: £ 573 to £
816 more
ICER: £ 3,496 to
£ 4,978 per
QALY
€ 4,073 to
€ 5,800
McEwan et al. [23]
Scenario 1-3
UK
NHS
40 years
(C 3.5%, E 3.5%)
Sanofi-Aventis
CUA
DES based on DCCT
- Severe: -25 to -28%
b
Nocturnal: -17 to
-22%
b
- Reduction by:
1. hypoglycaemia
2. fear of
hypoglycaemia
IU: 0.12 to 0.34
QALYs
IC: £ 1,043 to £
1,371 more
ICER: £ 8,807 to
£ 7,391 per
QALY
€ 8,943 to
€ 10,656
McEwan et al. [23]
Scenario 4
UK
NHS
40 years
(C 3.5%, E 3.5%)
Sanofi-Aventis
CUA
DES based on DCCT
-0.19% points
b - Reduction depending on
HbA1c reduction
Reduction by:
1. long-term
consequences
IU: 0.12 to 0.34
QALYs more
IC: about £
1,043 to £ 1,371
more
ICER: £ 1,096/
QALY
€ 11,818
Grima et al. [22]
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3Table 1 Main characteristics of modelling studies with GLA vs.NPH (listed in order of increasing ICER in ?€?/QALY
a) (Continued)
Canada
Canadian health ministry
36 years (C 5%, E 5%)
Sanofi-Aventis
CUA
State Transition Model
based on UKPDS and
DCCT
-0.4% points [34] - Reduction depending on
HbA1c reduction
Reduction by:
1. long-term
consequences
IU: 0.08 QALYs
more
IC: CAN$ 1,398
more
ICER: CAN$
20,799/QALY
€ 13,364
Warren et al. [20]
UK
NHS
9 years (C 3.5%, E 3.5%)
NICE
CUA
ScHARR Model
Only in sensitivity
analysis:
-0.14% points [33]
Symptomatic: -19% [20]
Severe: -52% [35]
Reduction depending on
HbA1c reduction
Reduction by:
1. hypoglycaemia
2. fear of
hypoglycaemia
3. long-term
consequences only in
sensitivity analysis
IU: n/a
IC: £ 962 more
ICER: £ 32,244/
QALY
€ 37,567
Cameron et al. [21]
Canada
Canadian health ministry
60 years
(C 5%, E 5%)
CADTH
CUA based on
CORE-Model
-0.11% points [5] Moderate: -18% [5]
Severe: -18% [5]
Reduction depending on
HbA1c reduction
Reduction by:
1. hypoglycaemia
2. fear of
hypoglycaemia only in
sensitivity analysis
3. long-term
consequences
IU: 0.039 QALYs
more
IC: CAN$ 3,423
more
ICER: CAN$
87,932/QALY
€ 57,002
Legends: C = costs, E = effects, UK = United Kingdom, CADTH = Canadian Agency, CUA = Cost-Utility-Analysis, QALY = quality adjusted life-year, CORE = Centre for Outcomes Research, DES = discrete event
simulation, NICE = National Institute for Health and Clinical Excellence, NHS = National Health Service, IU = incremental utilities, IC = incremental costs, ICER = incremental cost-effectiveness ratio, n/a = not
applicable, ScHARR = School of Health and Related Research (University of Sheffield).
aCurrencies transformed into Euro values via purchasing power parities (PPP),
bunpublished material
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Author/Study
(year of publication)
Brändle et al. [25] Cameron et al. [21] McEwan et al. [23] Grima et al. [22] Warren et al. [24] Warren et al. [20]
Research question clearly defined (✓)( ✓) ✓✓ ✓✓
Perspective named (✓)( ✓) ✓✓ ✓✓
Considered health effects HbA1c,
hypoglycaemia,
fear of hypogl.
HbA1c,
hypoglycaemia,
fear of hypogl.
1
HbA1c,
hypoglycaemia,
fear of hypogl.
HbA1c HbA1c
1,
hypoglycaemia,
fear of hypogl.
HbA1c
1,
hypoglycaemia,
fear of hypogl.
Source of efficacy data Meta-analysis
2,
Meta-regression
Meta-analysis Meta-analysis
2 RCT RCT Meta-analysis, RCT
Determination of efficacy via information synthesis - ✓✓ -- -
Complications of diabetes considered ✓✓✓ ✓ ✓
1 ✓
1
All relevant costs considered ✓ (✓)( ✓)( ✓)( ✓)( ✓)
Discounting (rate) C (3,5%),
E (3,5%)
C (5%),
E (5%)
C (3,5%),
E (3,5%)
C (5%),
E (5%)
C (3,5%),
E (3,5%)
C (3,5%),
E (3,5%)
Incremental analysis ✓✓✓ ✓ ✓ ✓
Sensitivity analysis ✓✓✓ ✓ ✓ ✓
Results of sensitivity analysis described ✓✓✓ ✓ ✓ (✓)
Results presented per capita ✓✓✓ ✓ ✓ ✓
Research question answered ✓✓✓ ✓ ✓ ✓
Strength and weakness of studies discussed - ✓ - ✓ (✓)( ✓)
Legends: C = cost, E = effectiveness, HbA1c = haemoglobin A1c, RCT = randomised controlled trial.
1Parameter included in sensitivity analysis only,
2unpublished material
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Author/Study Cameron et al.
[21]
Grima et al.
[22]
McEwan et al.
[23]
Brändle et al.
[25]
Warren et al.
[24]
Warren et al.
[20]
Health state Utility decrement
a Utility values
f Utility decrement
a Utility decrement
a Utility decrement
a
Data except for hypoglycaemia confidential to NICE
Ischaemic heart disease, first & subsequent years - - -0.09 -0.09 n/a n/a
Myocardial infarction, year of event -0.0409222 0.760 -0.066 -0.055 n/a n/a
Myocardial infarction, subsequent years -0.012 0.800 -0.066 -0.055 n/a n/a
Angina, year of event -0.0411989 - - - n/a n/a
Angina, subsequent years -0.024 - - - n/a n/a
Congestive heart failure, year of event -0.0546 0.693 -0.108 -0.108 n/a n/a
Congestive heart failure, subsequent years -0.018 0.693 -0.108 -0.108 n/a n/a
Stroke, year of event -0.0523513 0.720 -0.114 -0.164 n/a n/a
Stroke, subsequent years -0.040 0.800 -0.114 -0.164 n/a n/a
Peripheral vascular disease -0.021 - - - n/a n/a
Microalbuminuria -0.012 - - - n/a n/a
Proteinuria -0.017 - - - n/a n/a
ESRD, first and subsequent years - 0.644 -0.263 -0.263 n/a n/a
Dialysis, first & subsequent years -0.16 - -0.305 -0.305 n/a n/a
Funct. kidney transplant, first & subsequent years -0.03 - -0.075 -0.075 n/a n/a
Diabetic retinopathy -0.0155836 0.750 - - n/a n/a
Blindness and low vision -0.0497859 - - - n/a n/a
Pre-blind, first & subsequent years - - -0.029 -0.029 n/a n/a
Blind, first & subsequent years - - -0.074 -0.074 n/a n/a
Cataract -0.0170832 - - - n/a n/a
Macular edema -0.0170832 - - - n/a n/a
Neuropathy -0.0243702 - - - n/a n/a
Active uninfected diabetic ulcer -0.09 - - - n/a n/a
Active infected diabetic ulcer -0.14 - - - n/a n/a
Amputation -0.266 0.678 -0.28 -0.28 n/a n/a
Amputation, subsequent years - 0.800 - - n/a n/a
Fear of any hypoglycaemic episode - - - - -0.0019
d -0.0052
d
Severe hypoglycaemic episode -0.5485
b - -0.047
d -0.047
d -0.15
e -0.15
e
Mild/moderate hypoglycaemic episode -0.167
c -- - - -
Symptomatic hypoglycaemic episode - - -0.0142
d -0.0142
d --
Nocturnal hypoglycaemic episode - - -0.0084
d -0.0084
d --
Legend: ESRD = endstage renal disease
aapplied for 1-year (but not for subsequent years, hypoglycemic episodes and ulcers)
bdecrement for 24 hours
cdecrement for 15 minutes
dunclear duration
edecrement for 4 days
fnot additive, lowest utility in respective year is used
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3In general the utility decrements for long-term com-
plications used by McEwan et al. [23] and Brändle et al.
[25] are higher than those used by Cameron and Ben-
nett [21] (Table 3).
Significant methodological differences exist in dealing
with the influence of hypoglycaemic events on quality of
life. The following utility decrements were attributed by
Cameron and Bennett [21] to hypoglycaemic events:
0.0015 per severe and 0.0000048 per mild/moderate
hypoglycaemia and year.
Warren et al. [20,24], McEwan et al. [23] and Brändle et
al. [25] went even further and assumed, that quality of life
is not only affected by hypoglycaemia itself, but also by a
longer-lasting fear of this event. The derivation of utility
reduction was described by Currie et al. [37]. Patients with
type 1 diabetes were asked about frequency and severity of
hypoglycemic events during the last 3 months as well as
about their quality of life (via EQ-5D) and their fear of
hypoglycaemia (via Hypoglycaemia Fear Score, HFS). Fre-
quency and severity of hypoglycaemia were connected to
the HFS by means of regression models and afterwards
the HFS was linked to the EQ-5D values. For severe hypo-
glycaemia the utility decrement was 0.047 per event, for
symptomatic 0.0142 and nocturnal 0.0084, respectively.
The duration of the decrement remained unclear [37].
Input parameters: cost per unit consumed
It can be assumed that health care costs of diabetic
long-term consequences and hypoglycemic events were
considered properly in the included modelling studies.
Except Warren et al. [20,24] all studies report unit costs
and their sources for diabetic long-term complications.
The mean daily cost for GLA and NPH were not
reported in the studies of Warren et al. [20,24] and Brän-
dle et al. [25]. In the other studies the ratio of daily insulin
cost between GLA and NPH varies between 1.81 [23], 2.24
[22] and 2.53 [21]. As different insulin costs are likely to
have an impact on the results they should have been made
transparent.
As shown in a claims data analysis [26], the costs of nee-
dles, test strips or lancets significantly influence the cost of
diabetes care, it is important to mention, that only the
study of Brändle et al. [25] accounted for these costs.
Structure parameters of the models
All models discounted not only the costs arising in the
future but also the effects. Grima et al. [22] and Cameron
and Bennett [21] used a discount rate of 5%, the remain-
ing studies 3.5%. In the two studies of Warren et al.
[20,24] a time horizon of 9 years was chosen for model-
ling. In the other studies the horizon was 36 [22], 40
[23,25][ and 60 years [21].
Outcome parameter incremental cost-effectiveness ratio
In Table 1 the identified modelling studies are presented
in ascending order of their ICER value in purchasing
power parities (PPP).
A strict coherence between the characteristics of the
models and the ICER value cannot be deduced from this
evaluation. But there are plausible explanations for the
position of the respective study in the ranking order of
the table.
GLA was dominant compared to NPH in the study from
Brändle et al. [25]. Four aspects may have contributed to
this favourable result: (i) the authors utilised both the posi-
tive impact of the GLA therapy on the metabolic control
as well as on the frequency of hypoglycaemia; (ii) it is the
only modelling study in this review that accounted for the
costs of needles for insulin injection and disposables for
blood glucose self-monitoring; (iii) utility decrements
following the concept of fear of hypoglycaemia were
applied; (iv) furthermore Brändle et al. [25] as well as
McEwan et al. [23] used relatively high utility decrements
compared to Cameron und Bennett [21]. The smallest
ICER of € 3,859 per QALY gained is the result of scenario
5 from McEwan et al. [23]. In this model, which is a pre-
decessor of the one Brändle et al. [25] used, a comparably
high value for the HbA1c reduction of 0.45% points was
applied; the frequency of hypoglycaemia was assumed to
be the same for GLA and NPH.
In the studies on position 3 and 4, only a reduced fre-
quency of hypoglycaemia under GLA was considered.
Warren et al. [24] on position 3 used a reduced frequency
of symptomatic hypoglycaemia by 42% and of severe by
52%, which are the highest reductions identified in this
review. Compared to this McEwan et al. [23] with sce-
nario 1-3 used lower values: frequency of symptomatic
hypoglycaemia was reduced by 25-28% and of nocturnal
by 17-22%. Both studies apply the concept of utility
decrements related to the fear of hypoglycaemia. The
ICERs range between € 4,073 per QALY gained [24] and
€ 10,565 in scenario 1-3 [23].
An ICER of € 11,818 per QALY gained was the result
of the calculations in scenario 4 of McEwan et al. [23]. In
contrast to scenario 5, the authors adopted a conservative
value of the additional HbA1c reduction under GLA by
0.19% points. The frequency of hypoglycaemia is main-
tained equal for GLA and NPH.
Grima et al. [22] only used an additional HbA1c
reduction of 0.40% points under GLA in their model,
resulting in an ICER of € 13,364 per QALY gained.
The next higher ICER of € 37,567 per QALY gained was
calculated with the earlier version of the ScHARR model
[20]. Compared to [24] it used more conservative values
for the reduction of hypoglycaemic events (symptomatic
-20%/severe -52%) and also for the utility decrement
related to fear of hypoglycaemia (-0.0019 versus -0.0052
per event).
The highest ICER value of € 57,003 per QALY gained
resulted from the study of Cameron und Bennett [21].
GLA showed an advantage in the HbA1c reduction
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Page 9 of 13(-0.11% points) as well as in the lower rate of hypogly-
caemia (moderate -18%/severe -18%) over NPH. The
discount rate used was 5%. Utilities were not decreased
by the fear of hypoglycaemia. Overall the utility decre-
ments were lower than those used by McEwan et al.
[23] and Brändle et al. [25] (see table 3).
Claims data analysis
One claims data analysis [26] comparing GLA to NPH
was included in the evaluation. It has not yet been pub-
l i s h e db u tw a sm a d ea c c e s s i b l eb yt h es p o n s o ra sf u l l
study report. This retrospective cohort study was done
using German Statutory Health Insurance (SHI) claims
data of type 1 diabetes patients treated with GLA (n =
656) or NPH (n = 638) in a cost-minimisation study.
Quality assessment of claims data analysis
Analyses of claims data are retrospective observational
evaluations. Therefore, we applied different quality cri-
teria compared to the modelling studies [16].
The included claims data analysis showed good quality
concerning the description of main characteristics of the
study design and the observed population. Also, confoun-
der control via propensity score matching, the use of non-
parametric tests for statistical analyses, and the description
of the results were classified as adequate. Due to incom-
pleteness of data, no costs of needles and lancets were cal-
culated. The documentation of unit costs of insulin and of
test strips used is missing in the report.
Outcome parameters
The average costs of all diabetes-specific outpatient pre-
scriptions (long- and short-acting insulins, test strips) in
the 15 months period were € 200 higher in patients with
GLA than in NPH patients (p < 0.001). Patients treated
with GLA consumed less but more expensive long-acting
insulin (Δ € 124; p < 0.001) as well as more and costlier
short-acting insulin (Δ € 63; p < 0.001). No difference was
found in the consumption and costs of test strips.
No difference could be identified in utilization of acute
hospital and emergency services, which was interpreted as
evidence that there was no difference in effectiveness
between both treatment strategies. Unfortunately, the eva-
luation did not account for the utilisation of insulin nee-
dles and lancets due to lack of data.
Discussion
We conducted a systematic review of health economic
evaluations comparing GLA versus NPH as the basal com-
ponent of an ICT in type 1 diabetes. 7 economic evalua-
tions from 4 different countries (Germany, Canada,
England, Switzerland) were included: 6 cost-utility analyses
based on complex modelling and 1 cost-comparison ana-
lysis based on claims data. In 1 cost-utility analysis GLA
was dominant over NPH due to 0.238 additional QALYs
gained together with cost savings of € 796 (time horizon
40 years). In the other 5 studies of this type additional
costs per QALY gained for treatment with GLA ranged
between € 3,859 and € 57,002.
There is no unique willingness-to-pay threshold for a
QALY across different countries. However NICE judges a
technology acceptable if the ICER is below £ 20,000 to £
30,000 (€ 23,577 to € 35,365, based on 2009 PPP values)
[38] and there are other statements that imply comparable
threshold values for other countries [39]. Taking the
upper threshold value into account, GLA would be judged
cost-effective in 4 of the 6 of CUAs identified.
The cost-comparison analysis in the German SHI setting
showed € 160 higher diabetes-specific costs per patient per
12 months for therapy with GLA compared to NPH.
The identified systematic reviews [27-31] only gave little
detail on health economic evaluations comparing GLA
versus NPH, all of them dealing with the GLA-NPH com-
parison among several other interventions related to type
1 diabetes. These reviews identified no additional studies
compared to our search and reported no additional
aspects.
Keeping in mind the challenges associated with model-
ling a chronic disease such as type 1 diabetes the methods
of health economic evaluation are highly developed in this
field of comparing different strategies of insulin therapy.
Overall the assessment of the quality of the studies
using standardised check lists revealed acceptable to
good quality of the included studies. General guidelines
and recommendations on health economic evaluations
[13,14,40] emphasise, that publications must be optimally
transparent about the model’s structure, the input data,
the algorithms used and the assumptions made in the
study. In a minority of publications the structure of the
model used could only be assumed. More transparency is
necessary in the presentation of unit costs. Especially pre-
cise information on unit prices of the compared insulins
was often missing.
More diligence should be spent on the presentation of
the utilities used. This is of paramount importance,
because these factors have a strong impact on the total
results of a cost-utility analysis. In some studies the period
corresponding to utility decrements incurred by hypogly-
caemia remained unclear or could only be determined
from other referenced articles. Furthermore, when com-
paring utility values for the same type of event between
different studies (Table 3), we found considerable differ-
ences. These differences pose a challenge to the compari-
son of economic evaluations. Our approach to coping with
this issue was to make the differences transparent as
shown in Table 3.
In some publications a clear research question and the
perspective of the health economic evaluation was miss-
ing. Also the discussion of strengths and weaknesses
was not always satisfying.
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obtained from meta-analyses that include all existing clini-
cal evidence [10,41].This has only been realised by Brändle
et al. [25], McEwan et al. [23] Cameron et al. [21] and
partly by Warren et al. [20]. Choice of a single RCT from
the pool of existing studies by the other evaluations was
weakly motivated. Information synthesis would have been
possible, because already in 2002, when the first evalua-
tions were done, several studies comparing GLA with
NPH in type 1 diabetes did exist.
Only 1-Brändle et al. [25]-out of 6 modelling studies
included cost of self-monitoring of blood glucose, which
is a substantial cost in insulin treatment (about 30% of
all prescription costs [26]).
Specifically for modelling of diabetes a consensus
panel of the American Diabetes Association (ADA) [15]
has developed recommendations, among which the most
important are:
- As diabetes affects multiple organ systems, the
models must include a wide range of complications.
- These complications of diabetes may take years or
decades to occur, therefore the time horizon of the
models must be sufficiently long.
- Because some of the diabetes complications greatly
reduce a person’s quality of life, this type of outcome
should be considered in any analysis. Cost-utility
analysis is the appropriate evaluation type for this.
These commonly accepted requirements for diabetes
models were fulfilled by all of the included modelling
studies.
However, the following issues are still under discus-
sion regarding diabetes models and long-acting insulin
analogues:
- The question has not been finally answered whether
the therapy with long-acting insulin analogues predo-
minantly affects frequency of hypoglycaemia or predo-
minantly affects metabolic control. Also a combination
of both effects seems possible. However all three possi-
bilities should be considered in a modelling study by
different scenarios based on adequate meta-analyses.
Another option is the use of results from an individual
patient data (IPD) meta-regression [7] as Brändle et al.
[25] did. Still the relationship between the effect of
GLA on HbA1c and on the frequency of hypoglycae-
mia as well as the use of this relationship in the eco-
nomic model are not sufficiently transparent.
- The concept of fear of hypoglycaemia, which influ-
ences quality of life beyond the event of hypoglycaemia
itself seems plausible. Though, there are only few data
available [37] and research on this should be improved.
In economic evaluation, results of alternatives with and
without utility reduction because of fear of hypoglycae-
mia should be clearly distinguishable.
- Until now, only few modelling studies consider the
differences in the consumption of needles, test strips
for blood glucose self-monitoring and lancets between
the different basal insulins in type 1 diabetes.
This last point clearly shows, that claims data analyses
and primary data collection of insulin consumption, test
strips, needles, and lancets are a useful and necessary sup-
plement to modelling studies. They provide the data of
real life resource consumption, which in the models may
be linked to clinical effectiveness and patient reported out-
comes (PRO) data.
The aim of this systematic review was to make the
results of the included evaluations comparable via different
methodical steps. First, all relevant information about
design, analysis and modelling techniques, input and out-
put parameters were extracted by standardised checklists.
Second, study quality was consistently evaluated by an
internationally standardised tool. Finally, costs per QALY
gained were converted into Euro using the purchasing
power parities. This was necessary in order to express dif-
ferent values of different studies in different countries in
comparable Euro values. The reference year of the original
analysis was maintained.
The study used published PPPs that were derived from a
general basket of goods and services. For the use in health
economic evaluations a basket specifically of health care
goods, e.g. drugs and supplies, and services, e.g. ambula-
tory and inpatient care services, may be more appropriate.
However, such a health care related basket of goods and
services does not yet exist [17].
Other reasons may as well restrict the comparability of
the included studies:
- The different economic evaluations are based on dif-
ferent health care settings and legislations, e.g. the
Canadian Medicare system, the National Health Ser-
vice (NHS) in the United Kingdom or the German
Statutory Health Insurance setting.
- The information about the economic evaluations
was not presented comparably transparent in all
publications.
- One publication was identified in compliance with
the pre-defined inclusion criteria from a congress
abstract database [25]. Data for the review was
obtained form the congress poster and by extensive
personal correspondence with the author. The inclu-
sion of work published in an international scientific
congress seemed justifiable in the rapidly evolving
research area of health economic evaluation.
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Six health economic modelling studies and 1 claims data
analysis comparing insulin glargine to NPH in type 1
diabetes has been analysed.
The incremental cost utility ratios (ICER) vary from
dominance to € 57,002, which are less acceptable to a
health care decision maker. Despite some limitations con-
cerning comparability mainly resulting from methodologi-
cal and country specific aspects, insulin glargine (GLA)
seems to offer good value for money compared to conven-
tional human insulin (NPH) in patients with type 1 dia-
betes treated with a basal bolus regimen.
Comparability between studies is limited. Still the results
of this review underline the importance of the following
issues in economic evaluation of insulin therapy: evidence
on efficacy of therapy from information synthesis, i.e.
meta-analysis or meta-regression, should be used. Quality
of life plays an important role in the evaluations and maxi-
mum transparency on the utilities applied is necessary.
The concept of utility decrements from fear of hypoglycae-
mia is plausible and should be investigated further. Future
evaluations of insulin therapy should include consumption
of consumables for insulin injection and blood glucose self
monitoring.
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